Amarillo Biosciences is an emerging specialty biopharmaceutical company working in Phase II human clinical trials with a well-characterized therapeutic agent, low-dose interferon alpha.

The interferon alpha in our oral formulation is produced naturally from human cells, not by recombinant technology.

We are studying this product in human clinical trials in several conditions where innovative and patient-friendly therapies are needed.

High-dose injectable interferon is currently used for the treatment of cancer, multiple sclerosis and hepatitis. Low-dose oral interferon has been shown to have fewer side effects and is less costly than high-dose injectable interferon.

Our management team and corporate partners are working to develop this therapy for the benefit of patients and physicians worldwide.

We have license to the technology from Texas A&M University and license agreements with five international partner companies.